Jentadueto

Metformin Hydrochloride and Linagliptin, the active ingredients in Jentadueto, are a biguanide and a DPP‑4 inhibitor presented as a tablet for oral use. They are indicated for the management of type 2 diabetes mellitus as an adjunct to diet and exercise in adult patients.

GNH USA supplies Jentadueto as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product is manufactured for the EU market under strict regulatory standards, ensuring consistent potency and safety throughout the supply chain.

Jentadueto is used in the management of type 2 diabetes mellitus, targeting glucose regulation pathways.

Type 2 diabetes mellitus: improves overall glycemic control when added to diet and exercise. Inadequate response to metformin alone: provides additional glucose‑lowering effect through DPP‑4 inhibition. Combination therapy: reduces HbA1c levels more effectively than either component alone.

Jentadueto may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: loose stools, often transient. - Abdominal discomfort: cramping or pain. - Headache: mild tension‑type headaches. - Nasopharyngitis: upper respiratory tract infection symptoms. - Dizziness: occasional light‑headedness.

Serious or Rare Side Effects: - Lactic acidosis: rare but life‑threatening metabolic disturbance. - Severe hypoglycemia: especially when combined with insulin or sulfonylureas. - Pancreatitis: acute inflammation of the pancreas. - Severe allergic reactions: rash, angioedema, or anaphylaxis. - Hepatic dysfunction: abnormal liver enzymes or liver injury. - Renal impairment worsening: may exacerbate kidney function decline.

Before prescribing Jentadueto, clinicians should evaluate patient-specific factors and monitor for potential complications.

Renal function: assess creatinine clearance before initiating and periodically monitor. Hepatic impairment: use with caution; avoid in severe hepatic disease. Risk of lactic acidosis: contraindicated in conditions predisposing to hypoxia. Pregnancy and lactation: safety not established; avoid unless benefits outweigh risks. Drug interactions: review concomitant medications that affect renal clearance or increase hypoglycemia risk. Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Jentadueto can interact with several medicines, requiring careful management to avoid adverse outcomes.

Major Interactions (Avoid): - Intravenous contrast agents in patients with renal impairment: increased risk of metformin‑associated lactic acidosis. - Combination with insulin or sulfonylureas: heightened risk of hypoglycemia. - Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise linagliptin plasma levels.

Moderate Interactions (Monitor Closely): - Diuretics (e.g., thiazides): may affect renal function and metformin clearance. - ACE inhibitors or ARBs: monitor renal function and serum potassium. - Excessive alcohol intake: can potentiate metformin's effect on lactate metabolism.